Why the study?
Does switching from clopidogrel to prasugrel reduce the prevalence of high platelet reactivity in patients during the maintenance phase after an ACS event?
Does switching from clopidogrel to prasugrel reduce the prevalence of high platelet reactivity in patients during the maintenance phase after an ACS event?
Switching ACS patients on maintenance clopidogrel to prasugrel significantly reduces the prevalence of high on-treatment platelet reactivity, independent of CYP2C19 genotype.
No takes yet. Share an insight, caveat, or question.
Prasugrel switch was associated with lower HPR in ACS maintenance; hypothesis-generating for clinical outcomes independent of genotype.
Angiolillo et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: